These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27144973)

  • 21. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models.
    Cao B; Su Y; Oskarsson M; Zhao P; Kort EJ; Fisher RJ; Wang LM; Vande Woude GF
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7443-8. PubMed ID: 11416216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.
    Coxon A; Rex K; Meyer S; Sun J; Sun J; Chen Q; Radinsky R; Kendall R; Burgess TL
    Mol Cancer Ther; 2009 May; 8(5):1119-25. PubMed ID: 19435874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy.
    Heideman DA; Overmeer RM; van Beusechem VW; Lamers WH; Hakvoort TB; Snijders PJ; Craanen ME; Offerhaus GJ; Meijer CJ; Gerritsen WR
    Cancer Gene Ther; 2005 Dec; 12(12):954-62. PubMed ID: 15905856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody.
    Lee JM; Kim B; Lee SB; Jeong Y; Oh YM; Song YJ; Jung S; Choi J; Lee S; Cheong KH; Kim DU; Park HW; Han YK; Kim GW; Choi H; Song PH; Kim KA
    Oncogene; 2014 Jan; 33(1):34-43. PubMed ID: 23208509
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.
    Luraghi P; Reato G; Cipriano E; Sassi F; Orzan F; Bigatto V; De Bacco F; Menietti E; Han M; Rideout WM; Perera T; Bertotti A; Trusolino L; Comoglio PM; Boccaccio C
    Cancer Res; 2014 Mar; 74(6):1857-69. PubMed ID: 24448239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
    Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
    Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.
    Sun ZJ; Wu Y; Hou WH; Wang YX; Yuan QY; Wang HJ; Yu M
    Oncotarget; 2017 Apr; 8(17):29067-29079. PubMed ID: 28404966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SOMG-833, a novel selective c-MET inhibitor, blocks c-MET-dependent neoplastic effects and exerts antitumor activity.
    Zhang HT; Wang L; Ai J; Chen Y; He CX; Ji YC; Huang M; Yang JY; Zhang A; Ding J; Geng MY
    J Pharmacol Exp Ther; 2014 Jul; 350(1):36-45. PubMed ID: 24741075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
    Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
    Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
    Martens T; Schmidt NO; Eckerich C; Fillbrandt R; Merchant M; Schwall R; Westphal M; Lamszus K
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6144-52. PubMed ID: 17062691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.
    Casaletto JB; Geddie ML; Abu-Yousif AO; Masson K; Fulgham A; Boudot A; Maiwald T; Kearns JD; Kohli N; Su S; Razlog M; Raue A; Kalra A; Håkansson M; Logan DT; Welin M; Chattopadhyay S; Harms BD; Nielsen UB; Schoeberl B; Lugovskoy AA; MacBeath G
    Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7533-7542. PubMed ID: 30898885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.
    Yang Y; Mandiyan S; Robinson BS; McMahon G
    Cancer Res; 2016 Oct; 76(19):5788-5797. PubMed ID: 27550450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab.
    Mai E; Zheng Z; Chen Y; Peng J; Severin C; Filvaroff E; Romero M; Mallet W; Kaur S; Gelzleichter T; Nijem I; Merchant M; Young JC
    Mol Cancer Ther; 2014 Feb; 13(2):540-52. PubMed ID: 24258345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities.
    Hong SW; Jung KH; Lee HS; Son MK; Yan HH; Kang NS; Lee J; Hong SS
    Carcinogenesis; 2013 Sep; 34(9):2156-69. PubMed ID: 23671132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma.
    Suzuki Y; Sakai K; Ueki J; Xu Q; Nakamura T; Shimada H; Nakamura T; Matsumoto K
    Int J Cancer; 2010 Oct; 127(8):1948-57. PubMed ID: 20104519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.
    Hu S; Fu W; Xu W; Yang Y; Cruz M; Berezov SD; Jorissen D; Takeda H; Zhu W
    Cancer Res; 2015 Jan; 75(1):159-70. PubMed ID: 25371409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.
    Vigna E; Chiriaco C; Cignetto S; Fontani L; Basilico C; Petronzelli F; Comoglio PM
    Mol Oncol; 2015 Nov; 9(9):1760-72. PubMed ID: 26119717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis.
    Abounader R; Lal B; Luddy C; Koe G; Davidson B; Rosen EM; Laterra J
    FASEB J; 2002 Jan; 16(1):108-10. PubMed ID: 11729097
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.
    Estupina P; Fontayne A; Barret JM; Kersual N; Dubreuil O; Le Blay M; Pichard A; Jarlier M; Pugnière M; Chauvin M; Chardès T; Pouget JP; Deshayes E; Rossignol A; Abache T; de Romeuf C; Terrier A; Verhaeghe L; Gaucher C; Prost JF; Pèlegrin A; Navarro-Teulon I
    Oncotarget; 2017 Jun; 8(23):37061-37079. PubMed ID: 28427157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.